Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Cyclin-Dependent Kinase 4
  • Liposarcoma
  • Piperazines
  • Pyridines

abstract

  • Treatment with the CDK4 inhibitor PD0332991 was associated with a favorable progression-free rate in patients with CDK4-amplified and RB-expressing WDLS/DDLS who had progressive disease despite systemic therapy.

publication date

  • June 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3661937

Digital Object Identifier (DOI)

  • 10.1200/JCO.2012.46.5476

PubMed ID

  • 23569312

Additional Document Info

start page

  • 2024

end page

  • 8

volume

  • 31

number

  • 16